Seroatlas · Human Serome Atlas

TRA2A

Transformer-2 protein homolog alpha

Also known as: AWMS1, htra-2-alpha, TRA2A_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q13595
Gene: TRA2A
Ensembl: ENSG00000164548
Chromosome: 7
Canonical length: 282 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nucleoli,Vesicles

OverviewNCBI Gene

This gene is a member of the transformer 2 homolog family and encodes a protein with several RRM (RNA recognition motif) domains. This phosphorylated nuclear protein binds to specific RNA sequences and plays a role in the regulation of pre-mRNA splicing. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Sep 2013]

Canonical amino-acid sequenceUniProt

282 residues, UniProt reviewed canonical sequence.

>Q13595|TRA2A
     1  MSDVEENNFE GRESRSQSKS PTGTPARVKS ESRSGSRSPS RVSKHSESHS RSRSKSRSRS
    61  RRHSHRRYTR SRSHSHSHRR RSRSRSYTPE YRRRRSRSHS PMSNRRRHTG SRANPDPNTC
   121  LGVFGLSLYT TERDLREVFS RYGPLSGVNV VYDQRTGRSR GFAFVYFERI DDSKEAMERA
   181  NGMELDGRRI RVDYSITKRA HTPTPGIYMG RPTHSGGGGG GGGGGGGGGG GRRRDSYYDR
   241  GYDRGYDRYE DYDYRYRRRS PSPYYSRYRS RSRSRSYSPR RY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRA2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.59
Highest tissue expression: 105 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 105 nTPM
ovary: 52 nTPM
spleen: 51 nTPM
tonsil: 50 nTPM
cerebellum: 49 nTPM
esophagus: 46 nTPM

Single-cell type

neutrophils: 584 nCPM
neutrophil progenitors: 543 nCPM
esophageal apical cells: 511 nCPM
thyrotrophs: 377 nCPM
b-cells: 370 nCPM
somatotrophs: 367 nCPM

Immune cell

plasmacytoid DC: 30 nTPM
intermediate monocyte: 29 nTPM
non-classical monocyte: 27 nTPM
T-reg: 25 nTPM
neutrophil: 25 nTPM
gdT-cell: 25 nTPM

Brain region

white matter: 42 nTPM
choroid plexus: 28 nTPM
basal ganglia: 28 nTPM
hypothalamus: 28 nTPM
medulla oblongata: 28 nTPM
cerebral cortex: 27 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.59
gnomAD pLI: 0.01
gnomAD missense Z: 1.69
DepMap mean gene effect: -0.09
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

RNA binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TRA2A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRA2A as an antibody target. Whether an autoantibody or antibody against TRA2A could matter depends on whether native TRA2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRA2A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRA2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...